Medpace Holdings, Inc. Reports Third Quarter 2026 Results
Medpace reported Q3 2026 revenue of $716.0 million, up 8.5% year-over-year, with net new business awards of $873.4 million, up 10.6%. GAAP net income rose to $137.5 million, or $4.84 per diluted share (vs. $3.86 a year ago), with net income margin expanding to 19.2% from 16.8%, and EBITDA grew 16.0% to $172.1 million at a 24.0% margin. Backlog reached $3.17 billion, up 5.6% YoY, and the company generated $216.6 million in operating cash flow during the quarter, ending with $705.3 million in cash.
Key figures
- Eps
- 4.84
- Revenue
- 716000000
- Guidance
- FY2026 revenue $2.835B-$2.855B (12.0-12.8% growth); GAAP net income $514.0M-$524.0M; diluted EPS $17.97-$18.32; EBITDA $638.0M-$652.0M
- Revenue Yoy
- 8.5%
- Ebitda
- 172100000
- Ebitda yoy
- 16.0%
- Net income
- 137500000
- Backlog yoy
- 5.6%
- Ebitda margin
- 24.0%
- Net income margin
- 19.2%
- Cash and equivalents
- 705300000
- Operating cash flow q3
- 216600000
- Backlog conversion rate
- 23.8%
- Net new business awards
- 873400000
- Prior buyback remaining
- 527000000
- New buyback authorization
- $1.0 billion through December 31, 2028
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.